Efficacy of Permanent Pacing in the
Background. From the international long QT syndrome (LQTS) study, 30 patients with corrected QT interval (QTj) of more than 0.44 second'Z were identified who had permanent pacemakers implanted for management of recurrent syncope or aborted cardiac arrest.
Methods and Results. Pacemakers were implanted on average 7 years after the onset of the first syncopal episode. Most of the patients were female (87%), the average age at implantation was 19+ 13 years, the mean QT, was 0.55 ±0.08 second, and 57% were receiving antiadrenergic treatment for LQTS when the pacemaker was placed. Using birth as the time origin, the median cardiac event rate was significantly (p<0.001) reduced by pacing from 0.5 to 0 events per patient per year, with 21 patients experiencing no cardiac events during an average pacemaker follow-up of 49 months per patient. In 10 patients in whom the demand atrial pacing rate was faster than the intrinsic sinus rate, the average heart rate was increased 23 beats/min (from 58 to 81 beats/min) with pacing with reduction in the QT interval from 0.59 seconds to 0.46 seconds.
Conclusions. The beneficial effects of pacing in high-risk LQTS patients probably relate to the prevention of bradycardia, pauses, and the shortening of long QT intervals -factors that are known to be arrhythmogenic in this syndrome. Permanent cardiac pacing reduces the rate of recurrent syncopal events in high-risk LQTS patients, but it does not provide complete protection. (Circulation 1991;84:1524-1529) T he long QT syndrome (LQTS) is an infrequently occurring disorder with a pattern of expression in families suggesting autosomal dominant12 and autosomal recessive34 inheritance. Affected family members have an unusual electrocardiographic repolarization abnormality (QT prolongation) and a propensity to arrhythmogenic syncope and fatal ventricular arrhythmias.5'6 The present therapy of choice is treatment with /3-blockers.6,7 Surgical treatment with left cervicothoracic sympathetic ganglionectomy has also been used in LQTS patients with recurrent syncope.7-9 The efficacy of pacemakers as a treatment option for LQTS has been reported.10-1'The largest pacemaker study to date was published by Eldar et al in 1987.14 This group reported favorable pacemaker results in eight LOTS patients during a mean follow-up of 35 months per patient. From our international LQTS study, we have identified 30 patients in whom pacemakers were implanted for management of recurrent syncope or aborted sudden death, with a mean follow-up of 49 months per patient. The purpose of this report is to detail the pacemaker results in this larger population to better evaluate the role of permanent pacing in the treatment of high-risk LQTS patients.
Methods
From our international prospective study of LQTS6 involving 1,016 patients with corrected QT intervals (QTj) of more than 0.44 secl'2, 30 patients under 60 years of age were identified who had permanent pacemakers implanted between October 1977 and September 1989 for the management of recurrent syncope. All pacemaker-treated patients had QTc of more than 0.44 sec1"2. Clinical data regarding patient characteristics and cardiac events before and after initiation of pacemaker therapy were recorded on prospectively designed data forms as part of the ongoing LQTS study. Cardiac events included syncope (abrupt loss of consciousness with spontaneous resolution), aborted cardiac arrest (nonfatal cardiac arrest that required electrical defibrillation), and death from any cause after pacemaker implantation.
Medical and surgical therapy including the type and model of pacemaker and the technique of implantation were decided by each patient's attending physician. The therapy rendered was not part of any protocol.
The nonparametric, two-sided, paired Wilcoxon signed rank test'5 was used to evaluate the significance of the difference in the median cardiac event rates before versus after pacemaker implantation. In these analyses, birth was used as the time origin before pacemaker therapy. The Wilcoxon nonparametric analytic procedure was used because the cardiac event rates had nonnormal distribution, and the median event rates were a better measure of central tendency than the mean.
Results

Population Characteristics
The clinical characteristics of the 30 LQTS patients with implanted pacemakers are presented in Table 1 . All of the patients had experienced one or more episodes of syncope and/or aborted cardiac arrest before the pacemaker was implanted. The patients were predominantly young females. Twentyone patients were receiving 13-blocker therapy before implantation of the pacemaker, and three of these patients had previously undergone left cervicothoracic sympathetic ganglionectomy. The specific indications for pacemaker implantation were recurrent syncope or aborted cardiac arrest refractory to antiadrenergic therapy in 14 patients (47%), symptomatic bradycardia with 13-blockers in three patients (10%), syncope or aborted cardiac arrest without antiadrenergic therapy in 11 patients (36%), and symptomatic sinus bradycardia without antiadrenergic therapy in two patients (7%). The pacemaker was implanted on average 7 years after the onset of the first syncopal event. Seventy-nine percent of the patients had single chamber pacemakers (48% atrial demand pacer; 52% ventricular demand pacer and 21% had dual chamber units; in one patient, the type of pacemaker was not identified. The mean pacing rate was 10 beats/min faster than the first recorded heart rate, but QT, was similar before (QT =0.54+ 0.08 second) and after (0.53+±0.07 second) pacing.
Pacing Results
The pertinent patient characteristics including the duration of observation, the number of cardiac events, and the cardiac event rate before and after pacemaker implantation are presented in Table 2 for each of the 30 patients. The event rate is reduced in 24 of the 30 patients, and 21 patients experienced no cardiac events after pacemaker therapy. A summary tRepetitive ventricular arrhythmia includes nonsustained or sustained ventricular tachycardia, torsade de pointes, or ventricular fibrillation with resuscitation documented on an electrocardiogram or Holter recording before enrollment.
*Pacing rate was obtained in the 13 patients in whom the pacing rate was faster than the intrinsic heart rate. of the clinical data in the nine patients who experienced recurrent arrhythmic events after pacemaker implantation is presented in Table 3 . Eight of the nine patients were on antiadrenergic therapy at the time of the recurrent events. The individual cardiac event rates before (using birth as the time origin) and after (from implantation to last follow-up) pacemaker therapy are graphically presented in Figure 1 . A statistical summary of the findings is presented in Table 4 . The median cardiac event rate (events per patient per year) was significantly (p<0.001) reduced by pacing. The findings were even more significant when the first recorded cardiac event was used as the time origin. One patient, an infant with six cardiac events in the first 3 months of life, died 18 months after pacemaker implantation (patient 3), and this occurred at a time when the pacemaker was thought to be working properly. Nine patients had 3-blocker therapy initiated prophylactically after pacemaker placement, and two of these patients had recurrent syncope. Four patients had left cervicothoracic sympathetic ganglionectomy initiated after pacemaker implantation; two prophylactically because of persistent complex ventricular ectopy and two because of recurrent syncope. Since 28 of the 30 paced patients tTime duration from pacemaker implantation to last follow-up. tSudden death. §Aborted cardiac arrest. were receiving antiadrenergic therapy (p-blockers or sympathetic ganglionectomy), we were not able to evaluate whether recurrent events were favorably affected by the antiadrenergic treatment.
Pacing Rate
In the patients in whom the pacing rate was known (n = 19), the average pacing rate was similar in those with and without subsequent cardiac events (pacing rate: 69±8 beats/min in six with events and 75+±11 beats/min in 13 without events; t=1.41;p=0.18). The effect of pacing on repolarization parameters was evaluated in the 10 patients in whom the demand atrial pacing rate was faster than the intrinsic sinus rate on available postpacemaker tracings. A compar-ison of heart rate, cycle length, QT, and QT, before and during pacing is presented in Table 5 . The average heart rate was increased 23 beats/min with pacing (from 58 to 81 beats/min), with a significant (p<0.01) reduction in QT and a nonsignificant (p=0.12) reduction in QTc. The QT and QT, values obtained during several atrial pacing rates ranging from 54 to 93 beats/min in one LQTS patient are graphically presented in Figure 2 . There is a positive linear relation between QT and RR cycle length over the range of heart rates explored, with a nearly constant QTC interval at the various pacing rates.
Discussion
Permanent cardiac pacing was associated with a significant reduction in recurrent syncopal events in 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30 Mean±SD Median this high-risk LQTS population. All patients had experienced syncope and/or aborted cardiac arrest before pacemaker therapy. Most of the patients were receiving ,/3blocker therapy, and three patients had undergone left cervicothoracic sympathetic ganglionectomy before initiation of permanent cardiac pacing. The findings from this pacing experience with 30 LQTS patients are similar to the results reported in 1987 by Eldar their antiadrenergic effects. /3-Blockers are the first line of therapy in this disorder. In some LQTS patients, /3-blockers may accentuate sinus bradycardia or sinus pauses that can further prolong repolarization and provoke pause-dependent afterdepolarizations and triggered arrhythmias of the torsade de pointes type. Permanent pacing prevents bradycardia and pauses, and it might contribute to more homogeneous repolarization. Thus, there is physiological rationale for combining /3-blockers and permanent pacing in the treatment of high-risk LQTS patients.
No interpretation can be made about the relative efficacy of atrial, ventricular, or dual chamber pacing in preventing recurrent syncope in this population. Many patients with LOTS have such long repolarization phenomena that atrioventricular block can develop even at physiological atrial pacing rates. Thus, if atrial pacing is selected as the modality of pacing, it is essential to evaluate the heart rate response to various pacing rates and to vagal stimulation and after /3-blocker administration to ensure one-to-one conduction without atrioventricular block. Dual chamber pacemakers provide optimal flexibility for long-term pacing in this syndrome.
It is unclear what pacing rate should be selected for the management of high-risk LQTS patients. Keren et a119 found that prolongation of the actual (uncorrected) QT interval was more strongly associated with the occurrence of torsades de pointes than was prolongation of QTc. A pacing rate of 60 beats/ min prevents sinus pauses and profound bradycardia but does not meaningfully shorten the QT interval. As shown in Table 5 and Figure 2 , the QT interval shortens with increased atrial pacing rates with only a modest effect on QTc. Clearly, a demand pacing rate of 80 beats/min is more effective in shortening the QT interval than a pacing rate of 60 beats/min. At present, we recommend pacing rates in the 70-80 beats/min range to start, with faster pacing rates should recurrent syncope develop.
This study has several limitations. The findings reported herein are derived from a retrospective review of clinical data recorded in our prospective longitudinal LQTS investigation. The patients were not randomized to pacemaker therapy. Rather, pacemaker treatment was initiated by the attending cardiologist because of syncope or aborted cardiac arrest that was either refractory to conventional measures or associated with profound sinus bradycardia. Of note, three patients who had recurrent syncope despite left cervicothoracic sympathetic ganglionectomy before pacing remained free of syncope after pacing. The initiation of /3-blocker and/or left cervicothoracic sympathetic ganglionectomy in several patients after implantation of the pacemaker confounds a clear interpretation of the magnitude of the cause-and-effect relation between pacing and the reduction in recurrent cardiac events observed in this series. The occurrence of recurrent syncope (seven patients), one aborted cardiac arrest, and one sudden death after pacemaker implantation indicates that pacing provides incomplete protection against malignant arrhythmias in high-risk LQTS patients.
We used birth as the starting point in calculating the event rate before initiation of pacing. With this approach, the exposure before pacemaker implantation was considerably longer (median 241 months) than the duration of follow-up after pacing (median 28 months). This imbalance could create some bias regarding the observed results. We tried to adjust for this before/after exposure discrepancy by reporting the results in terms of median event rates, thus taking into account the exposure duration. An alternative approach is to use the first cardiac event as the starting point, but this creates a selection bias resulting in a much higher event rate before pacingmaking pacing look even better than what is reported. A third approach is to do a case-control match of the exposure before and after pacing.
Unfortunately, we could not do this because we did not have data on the date of each event, only the number of events before and after pacing and the date of the first event before pacing.
Despite these limitations, it is likely that pacemaker therapy was responsible for reducing the rate of recurrent syncopal events in this high-risk LQTS population. Our current therapeutic recommendations are as follows. Patients with LQTS who develop syncope should be treated with /3-blockers. If symptomatic bradycardia develops, pacemaker therapy should be initiated. If recurrent syncope develops on /3-blockers, then two therapeutic options are available: either permanent pacing or left cervicothoracic sympathetic ganglionectomy.69 We do not have any comparative data to indicate a preference for one of these therapies over the other in high-risk LQTS patients. However, if the use of either one of these two interventions in combination with p-blockers does not control recurrent syncope, then triple therapy with fl-blockers, pacing, and ganglionectomy should be tried.
